Innovation

Cell & Gene Therapy

Taranis Capital and EEC Partner to Build Next-Generation Data Centres

Taranis Capital and Emaar Executive Company partner to develop carrier-neutral data centres across Saudi Arabia, supporting rising AI and cloud demand under Vision 2030

Taranis Capital Limited (“Taranis”), a DFSA-regulated investment firm based in Dubai International Financial Centre (DIFC), has signed a Memorandum of Understanding (MOU) with Emaar Executive Company (EEC) to develop, construct, and operate a portfolio of next-generation, carr

Mark Walker  · 
AgriTech

UAE's agritech push: food security as industrial policy

The Emirates Food Security Council has expanded its mandate to cover controlled-environment agriculture, cell-cultured protein, and desalination-linked aquaculture — with state capital behind each.

The UAE imports roughly 85 per cent of its food. For a country that has made state-capacity industrial policy a signature of its modernisation, that number is not a fact to be accepted — it is a problem to be solved with capital and technology.

The Biotech Times Editorial Team  · 
Regulatory Science

Incannex secures US patent for IHL-42X sleep apnoea therapy to 2040

Incannex Healthcare has won a USPTO patent covering its oral OSA combination therapy IHL-42X, with baseline protection running to July 2040.
Incannex Healthcare has won a USPTO patent covering its oral OSA combination therapy IHL-42X, with baseline protection running to July 2040.
The Biotech Times Editorial Team  · 
Biologics
Bioprocessing

Pluristyx secures Japan patent for synthetic mRNA iPSC reprogramming

The Seattle biotech's licensed mRNA technology cuts iPSC line generation to under 30 days, addressing a key bottleneck for commercial cell therapy manufacturing.
The Seattle biotech's licensed mRNA technology cuts iPSC line generation to under 30 days, addressing a key bottleneck for commercial cell therapy manufacturing.
The Biotech Times Editorial Team  · 

FocalTherics launches endometriosis HIFU programme in Europe

FocalTherics has treated initial patients at Toulouse University Hospital using its Focal One Robotic HIFU system for deep infiltrating endometriosis.
FocalTherics has treated initial patients at Toulouse University Hospital using its Focal One Robotic HIFU system for deep infiltrating endometriosis.
The Biotech Times Editorial Team  · 
Digital Health

SHARP launches first health smartwatch using HEALBE FLOW technology

SHARP's Karada Mate Watch integrates HEALBE's bioimpedance-based FLOW platform to estimate calorie intake and hydration automatically.
SHARP's Karada Mate Watch integrates HEALBE's bioimpedance-based FLOW platform to estimate calorie intake and hydration automatically.
The Biotech Times Editorial Team  · 
Regulatory Science

Cingulate secures first US patent on CTx-1301 ADHD tablet

The Kansas City biopharmaceutical company said US Patent No. 12,653,791 protects its trimodal dexmethylphenidate formulation through December 2042.
The Kansas City biopharmaceutical company said US Patent No. 12,653,791 protects its trimodal dexmethylphenidate formulation through December 2042.
The Biotech Times Editorial Team  · 
Diagnostics

Vilnius University physicists patent pea-sized triplex radiation sensor

A three-layer sensor developed at Vilnius University can detect, identify and locate radiation sources in real time, from lab doses to megagray nuclear emergency
A three-layer sensor developed at Vilnius University can detect, identify and locate radiation sources in real time, from lab doses to megagray nuclear emergency
The Biotech Times Editorial Team  · 
Biotech

BellaSeno pivotal trial enrols 30 women for absorbable breast scaffold

The Leipzig-based regenerative medtech firm reports 83% mean breast volume retention and zero scaffold-related complications in its first-in-human safety cohort.
The Leipzig-based regenerative medtech firm reports 83% mean breast volume retention and zero scaffold-related complications in its first-in-human safety cohort.
The Biotech Times Editorial Team  · 
Digital Health

Vibrant Gastro capsule used in JAMA Psychiatry gut-brain study

UCLA researchers used Vibrant's ingestible vibrating capsule to study gut-brain signalling as a predictor of relapse risk in anorexia nervosa recovery.
UCLA researchers used Vibrant's ingestible vibrating capsule to study gut-brain signalling as a predictor of relapse risk in anorexia nervosa recovery.
The Biotech Times Editorial Team  · 
Biologics
Regulatory Science

Novartis wins EC approval for Itvisma in broader SMA population

The European Commission has approved Itvisma as the first gene replacement therapy for SMA patients aged two and older, including teens and adults.
The European Commission has approved Itvisma as the first gene replacement therapy for SMA patients aged two and older, including teens and adults.
The Biotech Times Editorial Team  · 
Proteomics
Diagnostics

Seer wins EPO patent ruling and secures ITC probe into Nanomics

Seer has defended a key European proteomics patent and launched a US trade investigation targeting Nanomics' competing Proteonano products.
Seer has defended a key European proteomics patent and launched a US trade investigation targeting Nanomics' competing Proteonano products.
The Biotech Times Editorial Team  · 
Biologics
Regulatory Science

PolarityBio files BLA for SkinTE in diabetic foot ulcers

PolarityBio has submitted a BLA to the FDA for SkinTE, an autologous skin therapy backed by RMAT and Breakthrough Therapy designations.
PolarityBio has submitted a BLA to the FDA for SkinTE, an autologous skin therapy backed by RMAT and Breakthrough Therapy designations.
The Biotech Times Editorial Team  · 
Digital Health

Startup Coalition and DSIT launch Pitch in Whitehall competition

UK startups have until 24 July to apply for a government proof-of-concept contract under the Green Compute challenge.
UK startups have until 24 July to apply for a government proof-of-concept contract under the Green Compute challenge.
The Biotech Times Editorial Team  · 
Biologics

4DMT completes 4FRONT-2 Phase 3 enrolment four months ahead of schedule

4D Molecular Therapeutics has finished global enrolment for its wet AMD gene therapy trial, with topline 52-week data expected in the second half of
4D Molecular Therapeutics has finished global enrolment for its wet AMD gene therapy trial, with topline 52-week data expected in the second half of
The Biotech Times Editorial Team  · 
Regulatory Science

Serenity Medical wins FDA Breakthrough Device tag for tinnitus stent

The Shepherd Stent System targets venous sinus stenosis in severe pulsatile tinnitus, a condition linked to depression and elevated suicide risk.
The Shepherd Stent System targets venous sinus stenosis in severe pulsatile tinnitus, a condition linked to depression and elevated suicide risk.
The Biotech Times Editorial Team  · 
Biologics
Regulatory Science

AdJane reports first human proof-of-concept for intranasal OMV vaccine

The Dutch biotech's Phase I data show its nOMV platform induced mucosal and systemic immunity in healthy adults, published in peer-reviewed journal Vaccines.
The Dutch biotech's Phase I data show its nOMV platform induced mucosal and systemic immunity in healthy adults, published in peer-reviewed journal Vaccines.
The Biotech Times Editorial Team  · 
Digital Health

Isle of Man names four winners of 2026 health innovation challenge

Four digital health companies were selected from 125 global entries to win the Isle of Man's annual Innovation Challenge on Health and Social Care.
Four digital health companies were selected from 125 global entries to win the Isle of Man's annual Innovation Challenge on Health and Social Care.
The Biotech Times Editorial Team  · 
Digital Health
Diagnostics

Firstsource and AppliedAI report 95% cuts in live AI deployments

Six months after a strategic equity deal, the partners say live deployments cut healthcare processing times by 93% and lifted admissions throughput up to tenfold.
Six months after a strategic equity deal, the partners say live deployments cut healthcare processing times by 93% and lifted admissions throughput up to tenfold.
The Biotech Times Editorial Team  · 
Biologics
Regulatory Science

INmune Bio wins MHRA PIP approval for Ebstrocel in RDEB

The MHRA cleared INmune Bio's paediatric investigation plan in under three months, keeping the company's 2026 UK marketing authorisation application on track.
The MHRA cleared INmune Bio's paediatric investigation plan in under three months, keeping the company's 2026 UK marketing authorisation application on track.
The Biotech Times Editorial Team  · 
Subscribe to Innovation